Cresco Labs

Columbia Care Announces Approval of Business Combination with Cresco Labs at Special Meeting of Shareholders

Retrieved on: 
Friday, July 8, 2022
Alternative Medicine, Health, Natural Resources, Cannabis, Amber, SEDAR, CEO, Report, Legislation, Company, Industry, 777, Circular, Proxy, Oil, Cannabis, Tablet, Seed, Entrepreneurship, Meeting, Risk, Private Securities Litigation Reform Act, Leadership, Date, Cresco Labs, Security (finance), Arrangement, Cannabist Kansai, EU

At the Meeting, a total of 169,938,646 Columbia Care Shares were represented in person or by proxy, representing 42.6% of the Columbia Care Shares issued and outstanding as of the close of business on May 10, 2022 (the Record Date) and entitled to vote at the Meeting as of the Record Date.

Key Points: 
  • At the Meeting, a total of 169,938,646 Columbia Care Shares were represented in person or by proxy, representing 42.6% of the Columbia Care Shares issued and outstanding as of the close of business on May 10, 2022 (the Record Date) and entitled to vote at the Meeting as of the Record Date.
  • We are grateful for the overwhelming support of our shareholders as we move forward with the combination with Cresco Labs that will reshape the industry and redefine leadership in cannabis, said Nicholas Vita, Co-Founder, CEO of Columbia Care.
  • Full details are contained in the Report of Voting Results for the Meeting, which has been filed on SEDAR at www.sedar.com .
  • Columbia Care operates 131 facilities including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development.

Leading Independent Advisory Firm Glass Lewis Joins ISS in Recommending Columbia Care Shareholders Vote FOR the Transaction with Cresco Labs

Retrieved on: 
Thursday, June 30, 2022
Alternative Medicine, Cannabis, Health, Agriculture, Natural Resources, Biotechnology, Amber, SEDAR, Patient, CEO, CL, NLRB v. Kentucky River Community Care, Inc., FSE, NEO, Legislation, Special, Arrangement, Company, CSE, 777, Circular, U.S. Securities and Exchange Commission, Person, Event, Institutional Shareholder Services, Oil, Cresco, Tablet, Seed, Entrepreneurship, SEC, Risk, Private Securities Litigation Reform Act, Cresco Labs, Security (finance), Management, Director, Cannabist Kansai, EU

Institutional Shareholder Services (ISS) has also recommended that shareholders vote in support of the transaction.

Key Points: 
  • Institutional Shareholder Services (ISS) has also recommended that shareholders vote in support of the transaction.
  • We are pleased that Glass Lewis also supports our Boards unanimous recommendation that shareholders vote FOR the transaction with Cresco, said Nicholas Vita, Co-Founder, CEO of Columbia Care.
  • In connection with the proposed transaction, Columbia Care has filed the Circular containing important information about the proposed transaction and related matters.
  • Additionally, Columbia Care and Cresco will file other relevant materials in connection with the proposed transaction with applicable securities regulatory authorities.

Leading Independent Advisory Firm ISS Recommends Columbia Care Shareholders Vote FOR the Transaction with Cresco Labs

Retrieved on: 
Wednesday, June 29, 2022
Alternative Medicine, Cannabis, Health, Agriculture, Natural Resources, Biotechnology, Amber, SEDAR, Patient, CEO, NLRB v. Kentucky River Community Care, Inc., FSE, NEO, Legislation, Special, Arrangement, Company, CSE, 777, Circular, U.S. Securities and Exchange Commission, ISS, Person, Event, Institutional Shareholder Services, Oil, Cresco, Tablet, Seed, Entrepreneurship, SEC, Risk, Private Securities Litigation Reform Act, Cresco Labs, Security (finance), Management, Director, Cannabist Kansai, EU

We are pleased that ISS supports our Boards unanimous recommendation that shareholders vote FOR the transaction with Cresco, said Nicholas Vita, Co-Founder, CEO of Columbia Care.

Key Points: 
  • We are pleased that ISS supports our Boards unanimous recommendation that shareholders vote FOR the transaction with Cresco, said Nicholas Vita, Co-Founder, CEO of Columbia Care.
  • The Columbia Care Board of Directors unanimously recommends that shareholders vote FOR the Arrangement.
  • In connection with the proposed transaction, Columbia Care has filed the Circular containing important information about the proposed transaction and related matters.
  • Additionally, Columbia Care and Cresco will file other relevant materials in connection with the proposed transaction with applicable securities regulatory authorities.

Cresco Labs Announces Conference Participation for June 2022

Retrieved on: 
Wednesday, June 1, 2022
Alternative Medicine, Retail, Health, Other Retail, Tobacco, Specialty, CL, CSE, Conference, Labs, Knowledge, National Energy Education Development Project, Social equity, Good news, Cresco Labs, Education, SEED, Drug, Lorenzo Remedi

Oppenheimer Consumer Growth and E-Commerce Conference, June 14, 2022 (virtual): Chief Executive Officer Charles Bachtell will participate in a fireside chat moderated by analyst Rupesh Parikh and management will participate in one-on-one meetings.

Key Points: 
  • Oppenheimer Consumer Growth and E-Commerce Conference, June 14, 2022 (virtual): Chief Executive Officer Charles Bachtell will participate in a fireside chat moderated by analyst Rupesh Parikh and management will participate in one-on-one meetings.
  • Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry.
  • Sunnyside, Cresco Labs national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers.
  • Learn more about Cresco Labs at www.crescolabs.com .

Cresco Labs Announces First Quarter 2022 Results

Retrieved on: 
Wednesday, May 18, 2022
Alternative Medicine, Retail, Health, Tobacco, Specialty, Food, Beverage, Corona Labs Inc., Education, Knowledge, Taffy (candy), Company, Sunnyside, Depreciation, RiverRun International Film Festival, CL, Environment, Webcast, Mission statement, SEDAR, Tax, Cresco Labs, Cresco, Nature, Three Months Gone, Total, Legislation, CSE, Industry, Inventory, Misrepresentation, Awareness, Sentence, Historical cost, National Energy Education Development Project, Impaired asset, Clio Awards, Eastern Time Zone, Social equity, FSE, Central, War, GAAP, Private Securities Litigation Reform Act, HSR, Acquisition, Entrepreneurship, CEO, Drug, Video game, Film, Bank, Security (finance), Online gambling

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (Cresco Labs or the Company), a vertically integrated, multi-state operator and the number one U.S. wholesaler of branded cannabis products, today released its financial results for the three months ended March 31, 2022.

Key Points: 
  • Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (Cresco Labs or the Company), a vertically integrated, multi-state operator and the number one U.S. wholesaler of branded cannabis products, today released its financial results for the three months ended March 31, 2022.
  • "Q1 was a solid quarter for the Cresco Labs team in a challenging environment for all consumer product categories.
  • We are pairing the best consumer brands with a broad, deep and strategic footprint, said Charles Bachtell, Co-Founder and CEO of Cresco Labs.
  • The compliance-focused foundation of both Cresco Labs and Columbia Care is helping ensure a smooth progression towards deal approval through a reasonable and manageable regulatory process.

Columbia Care Reports First Quarter 2022 Results

Retrieved on: 
Monday, May 16, 2022
Biotechnology, Alternative Medicine, Manufacturing, Other Manufacturing, Health, 777, Telephone, Net income, Company, Forecasting, EBITDA, Depreciation, Indian stock exchange, Disclosure, Goal, Mission statement, Cresco Labs, Review, Cresco, Investor relations, Form 10-Q, COVID-19, Adult, Marketing, Adjustment, Legislation, Internal Revenue Code, Oil, Industry, Risk, Internal Revenue Code section 409A, Amber, Tablet, GAAP, Seed, Acquisition, Disease, Medical device, Bank, Bookkeeping, Audit, EU, Cannabist Kansai

Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 18 U.S. jurisdictions and the EU.

Key Points: 
  • Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 18 U.S. jurisdictions and the EU.
  • Columbia Care operates 131 facilities including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development.
  • In this press release, Columbia Care refers to certain non-GAAP financial measures, including Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit and Adjusted Gross Margin.
  • Columbia Care considers certain non-GAAP measures to be meaningful indicators of the performance of its business.

Cresco Labs Announces the Expiration of the HSR Act Waiting Period for the Proposed Acquisition of Columbia Care

Retrieved on: 
Monday, May 16, 2022
Alternative Medicine, Other Retail, Health, Retail, Tobacco, 777, EDGAR, SEDAR, Cresco Labs, Legislation, Oil, Intention, Perception, Care, Amber, Tablet, Seed, Private Securities Litigation Reform Act, SEC, Risk management, EU, Cannabist Kansai

Columbia Care operates 131 facilities including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development.

Key Points: 
  • Columbia Care operates 131 facilities including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development.
  • Columbia Care is one of the original multi-state providers of medical cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets.
  • In 2021, the company launched Cannabist, its new retail brand, creating a national dispensary network that leverages proprietary technology platforms.
  • Words such as expects, continue, will, anticipates and intends or similar expressions are intended to identify forward-looking statements.

Cresco Labs to Report First Quarter 2022 Financial Results on May 18, 2022

Retrieved on: 
Friday, May 6, 2022
Alternative Medicine, Health, Retail, Tobacco, Specialty, Good news, Company, CSE, Cresco Labs, Webcast, Knowledge, CL, SEED, Education, Social equity, Labs, National Energy Education Development Project, Drug, Lorenzo Remedi

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (Cresco Labs or the Company), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced that it will report financial results for the first quarter ended March 31st, 2022 on Wednesday May 18th, 2022 before the market opens.

Key Points: 
  • Cresco Labs (CSE:CL) (OTCQX:CRLBF) (Cresco Labs or the Company), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced that it will report financial results for the first quarter ended March 31st, 2022 on Wednesday May 18th, 2022 before the market opens.
  • The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights.
  • Archived access to the webcast will be available for one year on the Cresco Labs investor relations website.
  • Sunnyside, Cresco Labs national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers.

Cresco Labs Announces Conference Participation for May 2022

Retrieved on: 
Wednesday, May 4, 2022
Alternative Medicine, Retail, Health, Other Retail, Tobacco, Specialty, Good news, CSE, Cresco Labs, Knowledge, CL, SEED, Education, Conference, Social equity, Labs, Education Development Center, Drug, Lorenzo Remedi

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (Cresco Labs or the Company), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced its executive team will participate in the following conferences in May 2022:

Key Points: 
  • Cresco Labs (CSE:CL) (OTCQX:CRLBF) (Cresco Labs or the Company), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced its executive team will participate in the following conferences in May 2022:
    Canaccord Genuity Virtual Cannabis Conference, May 11, 2022: Chief Executive Officer Charles Bachtell will participate in a fireside chat with analyst Derek Dley and management will participate in one-on-one meetings.
  • Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry.
  • Sunnyside, Cresco Labs national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers.
  • Learn more about Cresco Labs at www.crescolabs.com .

Following the Money as Cannabis Investment and M&A Booms

Retrieved on: 
Tuesday, May 3, 2022
Poseidon, Investment, Ecosystem, Columbia, Cannabis, Legislation, Cresco Labs, Acquisition, Industry, Growth, Equity Group Holdings, Mg (magazine), Intelligence, Financial services

LOS ANGELES, May 3, 2022 /PRNewswire/ -- There's no question: 2021 was a historic financial year for the cannabis industry. After 2020, which was characterized by plummeting investment and struggling businesses, 2021 generated 165% year-over-year growth in capital that revived the industry and gave many professionals an optimistic outlook toward the future. Marked by impressive acquisitions and billions of dollars in investments, the current cannabis financial landscape is flush with capital. So, how can hopeful entrepreneurs and established businesses follow the money? With mergers and acquisitions on the rise, top venture capital and private equity firms have advice about tapping into this promising market.

Key Points: 
  • Marked by impressive acquisitions and billions of dollars in investments, the current cannabis financial landscape is flush with capital.
  • Rapid industry growth has catalyzed not only investment but also significant mergers and acquisitions that are driving recent industry consolidation.
  • As founders of Poseidon Asset Management, a leading investor in the legal cannabis and hemp space, Emily and Morgan Paxhia are well-versed in the nuances of cannabis financing.
  • Poseidon is not the only firm on the scene: More than fifty private equity, angel and venture capital firms are active members of the cannabis investment ecosystem.